Pli­ant posts high-dose da­ta of oral IPF drug with 'quite fa­vor­able' safe­ty, out­lines tri­al plans

Pli­ant Ther­a­peu­tics re­port­ed Mon­day morn­ing that pa­tients who got the high dose of its oral drug for id­io­path­ic pul­monary fi­bro­sis, or IPF, saw their dis­ease sta­bi­lize. Im­por­tant­ly, Pli­ant not­ed its drug came with few treat­ment-re­lat­ed ad­verse events in a field where ap­proved op­tions have sub­stan­tial side ef­fects.

The ear­ly da­ta sent Pli­ant’s stock $PLRX up 50%, from around $22 to near­ly $35 a share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER